Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anika Therapeutics reports strong Q4 earnings, eyes growth opportunities

Anika Therapeutics delivered strong financial performance in Q4 2022, with revenue growth and strategic investments driving growth targets for 2023. The company is focused on product launches, expanding its portfolio, and preparing for the launch of the RevoMotion Reverse Shoulder System.
While facing challenges such as higher stock-based compensation and lower EBITDA expected in 2023, Anika remains optimistic about the value inflection point in 2023. The company's emphasis on growth initiatives and commercial optimization positions it for future opportunities.

Anika Therapeutics reports growth in core segments and strategic investments

Anika Therapeutics showed positive revenue growth in Q1, driven by core business segments.
Despite a net loss, Anika is strategically positioning itself as a global leader in joint preservation.
Investments in new products and regulatory progress with Cingal indicate a focus on innovation and expansion.
Maintaining strong gross margins amidst increased operating expenses highlights operational efficiency.

Anika Therapeutics posts robust Q2 results, eyes growth opportunities

Anika Therapeutics reported strong Q2 results, raising its revenue outlook for 2023.
Despite international challenges, the company sees opportunities for growth in key segments.
Progress in FDA approvals, partnerships, and new product launches position Anika for future success.
Maintaining a focus on innovation and market expansion will be crucial for sustained growth.

Anika Therapeutics raises guidance on strong Q3 performance and outlook

Anika Therapeutics showcased robust growth in key segments, leading to an optimistic outlook for the year. Despite challenges in restructuring sales operations, the company is well-positioned for continued success with a focus on profitability and new product launches.

Anika Therapeutics exceeds Q4 expectations, eyes Hyalofast's U.S. potential

Anika Therapeutics delivered robust financial performance, focusing on driving new products for growth and operational efficiency. The company aims to accelerate profitability targets and is on track with product launches, making strategic adjustments based on feedback.

Anika Therapeutics reports Q1 revenue growth and strategic product advancements

Anika Therapeutics demonstrated solid financial performance in Q1 2024, driven by revenue growth, cost reduction initiatives, and positive market feedback on key products.
While facing challenges such as FDA approval requirements and leadership transition, the company's strengths in product portfolio and distribution agreements position it well for future growth.
Opportunities in FDA designations, revenue growth expectations, and operational improvements present avenues for Anika to enhance market presence and financial performance in the coming quarters.

Anika Therapeutics reports Q3 revenue, focuses on core products

Anika Therapeutics faces challenges with workforce reduction and financial losses
However, strategic focus on core HA products and revenue reclassification show promise
Opportunities lie in revenue growth in the commercial channel and long-term investments
Overall, Anika Therapeutics aims for sustainable growth and value creation

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Anika (ANIK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anika (ANIK) Upgraded to Strong Buy: What Does It Mean for the Stock?

AudioCodes

Owens Corning

Overstock.com

Here are four stocks to watch, three of them moving on strong earnings.

4 Earnings Breakouts To Watch

Better-than-expected Q2 earnings results spurred investors' interest in the small biotech.

Why Anika Therapeutics Stock Crushed It Today

Wall Street wasn't nearly as optimistic as it should have been about the biotech's second quarter.

Anika Therapeutics Blows Past Q2 Earnings Estimates

Anika Therapeutics Inc (ANIK) CEO Joseph Darling on Q2 2019 Results - Earnings Call Transcript

On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.

What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?

Anika Therapeutics, Inc. (ANIK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Anika Therapeutics

Applied Genetic Technologies

Axovant Gene Therapies Ltd

Mallinckrodt PLC

Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.

Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

As of late, it has definitely been a great time to be an investor in Anika Therapeutics.

Will Anika Therapeutics Continue to Surge Higher?

Anika Therapeutics' (ANIK) CEO Joseph Darling on Q1 2019 Results - Earnings Call Transcript

Anika (ANIK) delivered earnings and revenue surprises of 47.62% and 14.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Q1 Earnings and Revenues Top Estimates

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anika Therapeutics (ANIK) Reports Next Week: Wall Street Expects Earnings Growth

News for Anika Therapeutics Stock (ANIK)